WIF1 and breast cancer: Previous study showed that WIF1 promoter was significantly hypermethylated in bladder mucosa samples compared with the adjacent samples, and 5-aza-2′-deoxycytidine treatment markedly decreased the methylation of WIF1 promoter, thereby upregulating WIF1 expression and inhibiting pathogenesis of BC via Wnt/β-catenin [26].